Cancercompass News: gynecological cancer
|
|
12/25/2008 Stopping Ovarian Cancer By Blocking Proteins Coded By Notorious Gene Ovarian cancer cells are "addicted" to a family of proteins produced by the notorious oncogene, MYC, and blocking these Myc proteins halts cell proliferation in the deadliest cancer of the female reproductive system, according to a presentation by University of California, Berkeley scientists at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco. In 30-60 percent of human ovarian tumors, MYC is overly active, or amplified, usually as a result of extra chromosomal copies of the cancer-causing gene. The extra MYC encourages the ovarian cells to manufacture too much c-Myc, a protein that regulates other genes involved in cellular growth and proliferation. The presence of excessive c-Myc... Read more at this website... 12/25/2008 Studies From Academic Medical Center, Department Of Radiotherapy Describe New Findings In Cervical Cancer Prognosis Research findings, 'Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery,' are discussed in a new report. "Tumor recurrence after surgery for cervical carcinoma is associated with high fatality and morbidity, forming a major therapeutic challenge. This paper presents our experience with treatment of this patient group by salvage radiotherapy with curative intent," scientists in Amsterdam, Netherlands report. "Thirty-five patients with a pelvic recurrence after hysterectomy received high-dose radiotherapy. A retrospective analysis of long-term outcome and prognostic factors was performed. After a median follow-up period of 12.1 years, actuarial 2-,5-and 10-year overall survival ra... Read more at this website... 12/25/2008 Fujirebio Diagnostics And Roche Diagnostics Sign Agreement For New Ovarian Cancer Test Fujirebio Diagnostics, Inc. and Roche Diagnostics announced a worldwide license and supply agreement for the HE4 ovarian cancer test. Under the agreement, Roche will develop an assay kit utilizing Fujirebio Diagnostics' HE4 test on its automated immunoassay analyzers. The HE4 test was developed by Fujirebio Diagnostics to be used in conjunction with the company's existing CA125 biomarker, the current gold standard for monitoring ovarian cancer. This combination of biomarkers, as published clinical data shows, provides clinicians with a diagnostic tool that can provide higher sensitivity and specificity than CA125 alone. Improved sensitivity and specificity should allow clinicians to distinguish between benign and malignant pelvic masses... Read more at this website... 12/22/2008 Encouraging Data On First Patients Who Have Completed Its Phase I/II Clinical Trial Of DCVax-l In Metastatic Ovarian Cancer BETHESDA, Md. -- Northwest Biotherapeutics, Inc. ("NWBT") today announced encouraging data on clinical responses in the first two case reports of patients who have completed the Company's Phase I/II clinical trial with DCVax(R)-L personalized cancer vaccine for recurrent, metastatic ovarian cancer. This trial is ongoing, and is treating "no option" patients who have already been treated with most or all major drugs currently available for recurrent, metastatic ovarian cancer (including carboplatin, paclitaxel, docetaxel, abraxane, gemcitabine and topotecan), and whose cancer has still continued to progress. In other recent clinical trials testing various drugs and drug combinations for recurrent ovarian cancer, the treate... Read more at this website... 12/18/2008 Houston Researchers Make Ovarian Cancer Breakthrough Scientists have identified two proteins in patients with ovarian cancer that, when prevalent, dramatically increase their chance for survival. Led by researchers at the University of Texas M.D. Anderson Cancer Center, the discovery marks a significant advance for an emerging area of basic science called RNA interference, which one day may transform medicine. After studying nearly 250 ovarian cancer patients, scientists found that woman with high levels of two proteins named Dicer and Drosha in their tumor cells had a median survival of 11 years. Patients with low levels of one or both proteins -- about 40 percent of those studied -- had a median survival of less than three years. The results are reported in today's issu... Read more at this website... 12/08/2008 Curis Announces Genentech's Initiation Of Phase II Clinical Trial In Advanced Ovarian Cancer With Hedgehog Pathway Inhibitor CAMBRIDGE, Mass. -- Curis, Inc., a drug development company seeking to develop next generation proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog pathway inhibitor, as a maintenance therapy for ovarian cancer patients in second or third complete remission. Under the companies' collaboration agreement, Curis will receive a $3 million cash payment from Genentech. "There is a significant unmet treatment need for patients with relapsed ovarian cancer," said Curis President and CEO Dan Passeri. "While many advanced ovarian cancer patients initially experience clinical remission... Read more at this website... 12/08/2008 Healthlinx Finds 98% Accuracy In Ovarian Cancer Test Trial MELBOURNE -- Diagnostics developer HealthLinx Ltd has trialled a new test for ovarian cancer, saying it has a 98 per cent accuracy rate in early stage diagnosis. The results of the initial trial on its second-generation test compares with a 60 percent accuracy rate for the world's most commonly used diagnostic, CA125, HealthLinx said on Monday. For the new test, HealthLinx substituted two new biomarkers - which highlight the presence of particular compounds in the blood and other body fluids - for two of the five biomarkers in its existing ovarian cancer diagnostic, OvPlex. OvPlex, the first-generation test, was launched in October. The company said it had a 92.9 percent accuracy in early stage diag... Read more at this website... |
